Oban BioPharma's OBT-676 Showcases Promising Preclinical Data

STAMFORD, Conn., Nov. 14, 2026 /CourierPR/ -- Oban BioPharma, a privately held biotechnology company, announced that its preclinical data for OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming Obesity Society's Annual Meeting, Obesity Week® 2026. The conference, taking place from November 14-17, 2026, in National Harbor, MD, will feature the presentation on Monday, November 16th, from 2:30pm to 3:30pm EST.

OBT-676 is a novel molecular entity that achieves potent full agonism at the amylin and calcitonin receptors (DACRA) while simultaneously delivering partial agonism across the GLP-1, GIP, and glucagon (Triple-G) pathways. The company conducted a 28-day diet-induced obesity (DIO) study in rats, where once-daily oral administration of OBT-676 resulted in rapid, sustained weight loss, with up to 17% weight reduction. Additionally, the study observed deep visceral fat depletion, with up to 42.5% reduction, and hepatic defatting. On Day 29, the oral glucose-tolerance test (oGTT) showed marked glycemic control with increased insulin sensitivity.

By successfully integrating potent dual amylin/calcitonin agonism with calibrated Triple-G pharmacology in a single oral small molecule, Oban BioPharma has validated its DACRA/Triple-G platform as a truly differentiated, disease-modifying modality for the treatment of obesity, type 2 diabetes, and broader metabolic indications consistent with this unique pharmacology.